Management of biliary tract cancers in early-onset patients: A nested multicenter retrospective study of the ACABI GERCOR PRONOBIL cohort.
biliary tract cancers
chemotherapy
cholangiocarcinoma
early onset
molecular testing
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
08 Apr 2024
08 Apr 2024
Historique:
revised:
28
02
2024
received:
07
01
2024
accepted:
19
03
2024
medline:
8
4
2024
pubmed:
8
4
2024
entrez:
8
4
2024
Statut:
aheadofprint
Résumé
Accumulating data has shown the rising incidence and poor prognosis of early-onset gastrointestinal cancers, but few data exist on biliary tract cancers (BTC). We aimed to analyse the clinico-pathological, molecular, therapeutic characteristics and prognosis of patients with early onset BTC (EOBTC, age ≤50 years at diagnosis), versus olders. We analysed patients diagnosed with intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder adenocarcinoma between 1 January 2003 and 30 June 2021. Baseline characteristics and treatment were described in each group and compared. Progression-free survival, overall survival and disease-free survival were estimated in each group using the Kaplan-Meier method. Overall, 1256 patients were included, 188 (15%) with EOBTC. Patients with EOBTC demonstrated fewer comorbidities (63.5% vs. 84.5%, p < .0001), higher tumour stage (cT3-4: 50.0% vs. 32.3%, p = .0162), bilobar liver involvement (47.8% vs. 32.1%, p = .0002), and metastatic disease (67.6% vs. 57.5%, p = .0097) compared to older. Patients with EOBTC received second-line therapy more frequently (89.5% vs. 81.0% non-EOBTC, p = .0224). For unresectable patients with BTC, median overall survival was 17.0 vs. 16.2 months (p = .0876), and median progression-free survival was 5.8 vs. 6.0 months (p = .8293), in EOBTC vs. older. In advanced stages, fewer actionable alterations were found in EOBTC (e.g., IDH1 mutations [7.8% vs. 16.6%]; FGFR2-fusion [11.7% vs. 8.9%]; p = .029). Patients with EOBTC have a more advanced disease at diagnosis, are treated more heavily at an advanced stage but show similar survival. A distinctive molecular profile enriched for FGRF2 fusions was found.
Sections du résumé
BACKGROUND & AIMS
OBJECTIVE
Accumulating data has shown the rising incidence and poor prognosis of early-onset gastrointestinal cancers, but few data exist on biliary tract cancers (BTC). We aimed to analyse the clinico-pathological, molecular, therapeutic characteristics and prognosis of patients with early onset BTC (EOBTC, age ≤50 years at diagnosis), versus olders.
METHODS
METHODS
We analysed patients diagnosed with intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder adenocarcinoma between 1 January 2003 and 30 June 2021. Baseline characteristics and treatment were described in each group and compared. Progression-free survival, overall survival and disease-free survival were estimated in each group using the Kaplan-Meier method.
RESULTS
RESULTS
Overall, 1256 patients were included, 188 (15%) with EOBTC. Patients with EOBTC demonstrated fewer comorbidities (63.5% vs. 84.5%, p < .0001), higher tumour stage (cT3-4: 50.0% vs. 32.3%, p = .0162), bilobar liver involvement (47.8% vs. 32.1%, p = .0002), and metastatic disease (67.6% vs. 57.5%, p = .0097) compared to older. Patients with EOBTC received second-line therapy more frequently (89.5% vs. 81.0% non-EOBTC, p = .0224). For unresectable patients with BTC, median overall survival was 17.0 vs. 16.2 months (p = .0876), and median progression-free survival was 5.8 vs. 6.0 months (p = .8293), in EOBTC vs. older. In advanced stages, fewer actionable alterations were found in EOBTC (e.g., IDH1 mutations [7.8% vs. 16.6%]; FGFR2-fusion [11.7% vs. 8.9%]; p = .029).
CONCLUSIONS
CONCLUSIONS
Patients with EOBTC have a more advanced disease at diagnosis, are treated more heavily at an advanced stage but show similar survival. A distinctive molecular profile enriched for FGRF2 fusions was found.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : GERCOR Group
Organisme : ARCAD (Aide et Recherche en Cancerologie Digestive) Foundation
Organisme : ACABi (Association pour l'étude des Cancers et Affections des voies Biliaires)
Informations de copyright
© 2024 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
Ugai T, Sasamoto N, Lee HY, et al. Is early‐onset cancer an emerging global epidemic? Current evidence and future implications. Nat Rev Clin Oncol. 2022;19(10):656‐673.
Zhao J, Xu L, Sun J, et al. Global trends in incidence, death, burden and risk factors of early‐onset cancer from 1990 to 2019. BMJ Oncol. 2023;2(1):e000049.
Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273‐1281.
Izquierdo‐Sanchez L, Lamarca A, La Casta A, et al. Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. J Hepatol. 2022;76(5):1109‐1121.
Sinicrope FA. Increasing incidence of early‐onset colorectal cancer. N Engl J Med. 2022;386(16):1547‐1558.
REACCT Collaborative, Zaborowski AM, Abdile A, et al. Characteristics of early‐onset vs late‐onset colorectal cancer: a review. JAMA Surg. 2021;156(9):865‐874.
Takeda T, Sasaki T, Inoue Y, et al. Early‐onset pancreatic cancer: clinical characteristics and survival outcomes. Pancreatology. 2022;22(4):507‐515.
Bergquist JR, Leiting JL, Habermann EB, et al. Early‐onset gastric cancer is a distinct disease with worrisome trends and oncogenic features. Surgery. 2019;166(4):547‐555.
Santoro R, Carboni F, Lepiane P, Ettorre GM, Santoro E. Clinicopathological features and prognosis of gastric cancer in young European adults. Br J Surg. 2007;94(6):737‐742.
Piciucchi M, Capurso G, Valente R, et al. Early onset pancreatic cancer: risk factors, presentation and outcome. Pancreatology. 2015;15(2):151‐155.
Defossez G. Estimations nationales de l'incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018 2019. https://www.santepubliquefrance.fr/maladies‐et‐traumatismes/cancers/cancer‐du‐sein/documents/rapport‐synthese/estimations‐nationales‐de‐l‐incidence‐et‐de‐la‐mortalite‐par‐cancer‐en‐france‐metropolitaine‐entre‐1990‐et‐2018‐volume‐1‐tumeurs‐solides‐etud
Feng H, Tong H, Yan J, He M, Chen W, Wang J. Genomic features and clinical characteristics of adolescents and young adults with cholangiocarcinoma. Front Oncol. 2019;9:1439.
Pappas L, Baiev I, Reyes S, et al. The Cholangiocarcinoma in the Young (CITY) study: tumor biology, treatment patterns, and survival outcomes in adolescent young adults with cholangiocarcinoma. JCO Precis Oncol. 2023;7:e2200594.
Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663‐673.
Fontana E, Meyers J, Sobrero A, et al. Early‐onset colorectal adenocarcinoma in the IDEA database: treatment adherence, toxicities, and outcomes with 3 and 6 months of adjuvant fluoropyrimidine and oxaliplatin. J Clin Oncol. 2021;39(36):4009‐4019.
Ntala C, Debernardi S, Feakins RM, Crnogorac‐Jurcevic T. Demographic, clinical, and pathological features of early onset pancreatic cancer patients. BMC Gastroenterol. 2018;18(1):139.
Castet F, Fabregat‐Franco C, Castillo G, et al. Clinical and genomic characterisation of early‐onset pancreatic cancer. Eur J Cancer. 2023;194:113338.
van Nistelrooij AMJ, van Marion R, PALGA‐Group, et al. Early onset esophageal adenocarcinoma: a distinct molecular entity? Onco Targets Ther. 2016;3(1):42‐48.
Neuzillet C, Emery C, Teissier C, Bouée S, Lièvre A. Patient healthcare trajectories of intrahepatic cholangiocarcinoma in France: a nationwide retrospective analysis. Lancet Reg Health Eur. 2022;15:100324.
Lamarca A, Palmer DH, Wasan HS, et al. Second‐line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC‐06): a phase 3, open‐label, randomised, controlled trial. Lancet Oncol. 2021;22(5):690‐701.
Verdaguer H, Saurí T, Acosta DA, et al. ESMO scale for clinical actionability of molecular targets driving targeted treatment in patients with cholangiocarcinoma. Clin Cancer Res. 2022;28(8):1662‐1671.